Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Tuesday, 8 August 2017

Sanofi Files Suit in the U.S. to Defend its Patent Rights on Lantus®

Sanofi    

Published: 21:31 CEST 08-08-2017 /GlobeNewswire /Source: Sanofi / : SAN /ISIN: FR0000120578


Sanofi Files Suit in the U.S. to Defend its Patent Rights on Lantus®

 

Paris, France - August 8, 2017 - Sanofi announced today that it filed a patent infringement suit against Merck Sharp & Dohme Corp. ("Merck") on August 8, 2017 in the United States District Court for the District of New Jersey. In its suit Sanofi alleges infringement of two patents.

 

The suit was triggered by a notification received from Merck in late June, in which Merck stated that it had filed an NDA (505(b)(2) New Drug Application) with FDA for an insulin glargine vial drug product. Merck also stated that its NDA included a paragraph IV certification challenging all of the Sanofi patents then listed in the FDA Orange Book for Sanofi's Lantus® and Lantus® SoloStar® products.

 

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

 

 

Contacts:

 

Media Relations

Ashleigh Koss

Tel: +1 (908) 981-8745

Mobile: +1 (908) 205-2572

Ashleigh.Koss@sanofi.com

Investor Relations

George Grofik

Tel. +33 (0) 1 53 77 45 45

ir@sanofi.com

 

 



Press release (PDF)



This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: Sanofi, 54 rue la Boetie, PARIS 75008, FRANCE
If you would like to unsubscribe and stop receiving these e-mails click here.